

# MARKET REPORT



## Abbott Laboratories (ABT) - Medical Equipment - Deals and Alliances Profile

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# Abbott Laboratories (ABT) - Medical Equipment - Deals and Alliances Profile

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)1300 321501 or **Email:** [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com)

# Abbott Laboratories (ABT) - Medical Equipment - Deals and Alliances Profile

## Summary

Abbott Laboratories (Abbott) develops, manufactures, and sells a diversified range of healthcare products including drugs, diagnostics, branded generics, and vascular and nutritional products. The company's products comprise specialized medicines; medical diagnostic instruments and tests; minimally invasive surgical devices; nutritional supplements for infants, children and adults; and products for veterinary care. It has research and development, manufacturing and administrative facilities across the world. The company markets its products in North America, Latin America, the Caribbean, the Middle East, Europe, Asia-Pacific and Africa. Abbott is headquartered in Abbott Park, Illinois, the US.

Abbott Laboratories (ABT) - Medical Equipment - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Medical eTrack deals database, and primary and secondary research.

## Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

#### Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note\*: Some sections may be missing if data is unavailable for the company.

## Additional Details

**Publisher** : Global Data  
**Reference** : GDME1255D  
**Number of Pages** : 211  
**Report Format** : PDF  
**Publisher Information** :

**GlobalData»**

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Global Market Research and Corporate Data

# Table Of Contents for Abbott Laboratories (ABT) - Medical Equipment - Deals and Alliances Profile [Report Updated: 16-10-2018]

- Table of Contents Table of Contents 3List of Tables 7List of Figures 9Abbott Laboratories, Medical Equipment, Deals By Year, 2012 to YTD 2018 10Abbott Laboratories, Medical Equipment Deals By Type, 2012 to YTD 2018 11Abbott Laboratories, Medical Equipment, Deals By Region, 2012 to YTD 2018 12Abbott Laboratories, Medical Equipment, Deals By Market, 2012 to YTD 2018 13Abbott Laboratories, Medical Equipment, Deals Summary, 2012 to YTD 2018 14Abbott Laboratories, Medical Equipment, Deal Details 20Asset Purchase 20Abbott Labs Plans to Acquire Medical Optics and Other Products 20Thoratec Acquires DuraHeart II Ventricular Assist System From Terumo For US\$56.5 Million 21Venture Financing 23Bigfoot Biomedical Raises USD55 Million in Final Tranche of Series B financing 23Kalila Medical Raises Funds Through Venture Financing 25Tendyne Raises US\$25 Million In Series C Financing 26Tendyne Raises US\$1 Million In Venture Financing 27Spinal Modulation Raises US\$40 Million In Venture Financing 28Tendyne Raises Additional US\$2.6 Million In Venture Financing 29Nanostim Raises US\$9.5 Million In Series C Financing 30Topera Raises US\$25 Million In Series C Financing 31Spinal Modulation Raises US\$2 Million In Venture Financing 32OptiMedica Raises US\$35 Million In Venture Financing 33Nanostim Raises US\$10 Million In Venture Financing 35Topera Raises US\$4 Million In Venture Financing 36Tendyne Raises US\$9 Million In Venture Financing 37Nanostim Raises US\$10 Million In Venture Financing 38Topera Raises US\$2.8 Million In Venture Financing 39IDev Technologies Raises US\$0.83 Million In Venture Financing 40Private Equity 41Pharos Capital Group Acquires Majority Stake in TechLab 41Exponent Private Equity Acquires BBI Diagnostics from Alere for USD162 Million 42Partnerships 43Abbott Lab Enters into Licensing Agreement with SurModics 43Abbott Labs Enters into Licensing Agreement with Beijing Strong Biotechnologies 44Axis-Shield Enters into Licensing Agreement with Hangzhou Joinstar Biomedical 45Insulet Extends Licensing Agreement with Abbott Diabetes Care 46BioPorto Diagnostics Enters Into Licensing Agreement With Abbott Labs 47Axis-Shield Diagnostic Enters into Licensing Agreement with Siemens Healthcare Diagnostics 48Robert Bosch Healthcare Systems Enters Into Licensing Agreement With Abbott Diabetes Care 49Abbott Enters Into Licensing Agreement With Stanford University For Prostate Cancer Biomarkers 50Insulet Amends Licensing Agreement With Abbott Diabetes 51Roxwood Medical Enters into Distribution Agreement with Abbott Vascular 52Abbott Labs and Bigfoot Biomedical Enter into Agreement 53Akers Biosciences Enters into Distribution Agreement with First Check Diagnostics 54Celgene and Agios Pharma Enter into Agreement with Abbott Labs 55Diasend Partners with Abbott Labs 56MATTER Enters into Agreement with Abbott 57Abbott Enters into Agreement with GE Healthcare 58Abbott Labs Enters into Agreement with Sekisui Diagnostics for Coagulation Testing 59Advanced Biological Enters into Agreement with Abbott for HIV Genotyping Data Analysis Software 60Abbott Labs Enters into Co-Development Agreement with US Department of Defense 61Abbott Molecular Enters into Co-Development Agreement with Biocartis 62Idera Pharma Enters Into Co-Development Agreement With Abbott Molecular For In Vitro Companion Diagnostic Test 63Abbott Enters Into Distribution Agreement With R-Pharm For Diabetes Care Products 64St. Jude Medical Enters Into Distribution Agreement With Spinal Modulation For Axium Neurostimulator System 65Epizyme Enters Into Co-Development Agreement With Abbott Labs 66BioGenex Labs Enters Into Co-Marketing Agreement With Abbott Molecular 67Cellavision Enters Into Distribution Agreement With Abbott 68Abbott Molecular Enters Into Agreement With Janssen Biotech And Pharmacylics For Leukemia Test 69BioView Enters Into Agreement With Abbott To Develop Automated Cancer Screening System 70Abaxis Enters Into Distribution Agreement With Abbott Point of Care For Piccolo Blood Chemistry System 71Alere Enters Into Co-Development Agreement With AT&T 72Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 73Abbott Vascular Enters Into Co-Marketing Agreement With St. Jude Medical 74Abbott Enters Into Co-Development Agreement With Genetics Lab For Molecular Assay Development 75Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCT Assay For Sepsis 76Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus 77Equity Offering 78Abbott Labs Plans to Raise USD3 Billion in Public Offering of Shares 78Debt Offering 79Abbott Labs Raises USD1.33 Billion in Public Offering of 1.5% Bonds Due 2026 79Abbott Labs Raises USD1.33 Billion in Public Offering of 0.875% Bonds Due 2023 80Abbott Labs Raises USD1.33 Billion in Public Offering of Bonds Due 2020 81Abbott Labs Raises USD3 Billion in Public Offering of 3.75% Notes due 2026 82Abbott Labs Raises USD1.5 Billion in Public Offering of 3.4% Notes Due 2023 84Abbott Labs Raises USD1.65 Billion in Public Offering of 4.75% Notes due 2036 86Abbott Labs Raises

USD2.85 Billion in Public Offering of 2.9% Notes due 2021 88Abbott Labs Raises USD2.85 Billion in Public Offering of 2.35% Notes due 2019 90Abbott Labs Raises USD3.25 Billion in Public Offering of 4.9% Notes due 2046 92Alere Raises USD425 Million in Private Placement of 6.37% Notes Due 2023 94Abbott Labs Raises USD750 Million in Public Offering of 2.55% Notes Due 2022 95Abbott Labs Raises USD1 Billion in Public Offering of 2.55% Notes Due 2025 96Abbott Labs Raises USD2.5 Billion in Public Offering of 2% Notes Due 2020 97Alere Completes Private Placement Of Notes Due 2020 For US\$425 Million 98St. Jude Medical Completes Public Offering Of Notes Due 2043 For US\$700 Million 99St. Jude Medical Completes Public Offering Of Notes Due 2023 For US\$900 Million 101Alere Completes Private Placement Of Notes Due 2018 For US\$450 Million 103Abbott Completes Private Placement Of Notes Due 2018 For US\$1 Billion 104Abbott Completes Private Placement Of Notes Due 2022 For US\$3.1 Billion 105Abbott Completes Private Placement Of Notes Due 2042 For US\$2.6 Billion 106Abbott Completes Private Placement Of Notes Due 2015 For US\$3.5 Billion 107Abbott Completes Private Placement Of Notes Due 2017 For US\$4 Billion 108Abbott Completes Private Placement Of Notes Due 2015 For US\$500 Million 109Asset Transactions 110Quidel Acquires Triage and BNP Business from Alere 110Terumo Acquires Portion of Vascular Closure Portfolio and Other Assets from St. Jude Medical and Abbott Labs for USD1.12 Billion 112QIAGEN Acquires Circulating Tumor Cell Technology from AdnaGen 114Coppersmith Capital Management Reportedly Wants Alere To Explore Sale Of Its Drug Testing And Toxicology Businesses For Up To US\$5 Billion 115Vascular Solutions Acquires Venture Catheter From St. Jude Medical For US\$3 Million 116Acquisition 117Siemens Healthineers Acquires Epcal from Alere 117Abbott Labs Acquires Alere 118Johnson & Johnson Acquires Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 120Abbott Labs Acquires St. Jude Medical for up to USD23.6 Billion 121Abbott Labs Acquires Kalila Medical 123St. Jude Medical Acquires Thoratec for USD3.3 Billion 124Abbott Labs Acquires Remaining Stake in Tendyne for USD250 Million 126Abbott Labs Enters into Option Agreement to Acquire Cephea Valve Technologies 127Abbott Labs Acquires Omnilab 128Alere Acquires US Diagnostics USD60 Million 129St. Jude Medical Acquires Spinal Modulation 130Abbott Labs Acquires Topera 131Abbott Labs Receives Right to Acquire Advanced Cardiac Therapeutics 132Ron Zwanziger Plans to Acquire Alere for USD3.82 Billion 133Jude Medical Completes Acquisition of NeuroTherm for USD200 Million 134St. Jude Medical Completes Acquisition of Remaining 81% Stake in CardioMEMS for USD450 Million 135St. Jude Medical Completes Acquisition Of Nanostim For US\$123.5 Million 137Abbott Laboratories Completes Acquisition Of IDev Technologies 139Abbott Labs Completes Acquisition Of OptiMedica For Up To USD410 Million 141St. Jude Medical Acquires Endosense, Developer Of Cardiovascular Devices 143Alere Completes Acquisition Of Epcal For Up To US\$241 Million 145Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 147Alere Acquires eScreen for USD296 Million 149Arriva Medical Acquires AmMed Direct For US\$23 Million 151STARLIMS Technologies Acquires Distribution Partners 152Arriva Medical Acquires Direct Diabetic Source 153Abbott Laboratories - Key Competitors 154Abbott Laboratories - Key Employees 155Abbott Laboratories - Locations And Subsidiaries 157Head Office 157Other Locations & Subsidiaries 157Recent Developments 175Financial Announcements 175Jul 18, 2018: Abbott reports second-Quarter 2018 Results 175Apr 18, 2018: Abbott Reports First-Quarter 2018 Results 178Jan 24, 2018: Abbott Reports Fourth-Quarter 2017 Results 181Oct 18, 2017: Abbott Reports Third-Quarter 2017 Results 184Jul 20, 2017: Abbott Reports Second-Quarter 2017 Results 187Apr 19, 2017: Abbott Reports First-Quarter 2017 Results 189Corporate Communications 191Aug 01, 2018: Global Healthcare Organizations join Abbott to launch the UNIVANTS of Healthcare Excellence Award 191Sep 22, 2017: Abbott and the Abbott Fund Provide \$2 Million in Additional Relief to Help Families Affected by Hurricane Maria and the Earthquake in Central Mexico 192Sep 18, 2017: Abbott and the Abbott Fund Expand Support for Hurricane Relief With \$1 Million to Help Families Affected by Hurricane Irma 193Sep 07, 2017: Abbott Named Industry Leader for Responsible and Sustainable Business for Five Consecutive Years on the Dow Jones Sustainability Index 194Aug 29, 2017: Abbott and the Abbott Fund Donate \$1 Million to Support Hurricane Harvey Relief Efforts 195Government and Public Interest 196Sep 06, 2018: Eighth Annual MedtechVision Conference to Focus on "The Impact of AI on Medicine" 196Jul 20, 2018: Rapid diagnostics deliver shared value 197Apr 17, 2018: Battery Performance Alert and Cybersecurity Firmware Updates for Certain Abbott (formerly St. Jude Medical) Implantable Cardiac Devices: FDA Safety Communication 199Product News 202Apr 17, 2018: Abbott Releases Planned Updates for Implantable Cardiac Devices 202Apr 11, 2018: Abbott Initiates Groundbreaking Study to Assess Superiority of High-Resolution Imaging Versus Standard-of-Care Angiography in Treating Coronary Artery Disease 203Oct 30, 2017: Analysis of Landmark Study Showed Patients Treated for Left-Main Coronary Artery Disease With Xience Stent Felt Better Faster and Had Similar Long-Term Outcomes to Open-Heart Surgery 204Aug 29, 2017: Abbott Issues New Updates for Implanted Cardiac Devices 205Jul 25, 2017: Abbott Initiates Clinical Trial Of Three-Month Dual Antiplatelet Therapy Following Implantation With Xience Coronary Stent 207Other Significant Developments 208Jul 28,

2018: FIND announces new wave of activities to address the challenges threatening hepatitis C elimination through potential diagnostic technologies 208Jun 19, 2018: ClearStar Expands Medical Testing with Abbott Laboratories Integration 209Aug 15, 2017: North West London Pathology and Abbott Partner for Diagnostics Products and Services, Including Alinity, in Three NHS Trusts 210Appendix 211Methodology 211About GlobalData 211Contact Us 211Disclaimer 211



# List Of Tables in Abbott Laboratories (ABT) - Medical Equipment - Deals and Alliances Profile [Report Updated: 16-10-2018]

## List of Tables

Abbott Laboratories, Medical Equipment, Key Facts, 2017	2
Abbott Laboratories, Medical Equipment, Deals Summary, 2012 to YTD 2018	2
Abbott Laboratories, Medical Equipment, Deals By Year, 2012 to YTD 2018	10
Abbott Laboratories, Medical Equipment Deals By Type, 2012 to YTD 2018	11
Abbott Laboratories, Medical Equipment, Deals By Region, 2012 to YTD 2018	12
Abbott Laboratories, Deals By Market, 2012 to YTD 2018	13
Abbott Laboratories, Medical Equipment, Deals Summary, 2012 to YTD 2018	14
Abbott Labs Plans to Acquire Medical Optics and Other Products	20
Thoratec Acquires DuraHeart II Ventricular Assist System From Terumo For US\$56.5 Million	21
Bigfoot Biomedical Raises USD55 Million in Final Tranche of Series B financing	23
Kalila Medical Raises Funds Through Venture Financing	25
Tendyne Raises US\$25 Million In Series C Financing	26
Tendyne Raises US\$1 Million In Venture Financing	27
Spinal Modulation Raises US\$40 Million In Venture Financing	28
Tendyne Raises Additional US\$2.6 Million In Venture Financing	29
Nanostim Raises US\$9.5 Million In Series C Financing	30
Topera Raises US\$25 Million In Series C Financing	31
Spinal Modulation Raises US\$2 Million In Venture Financing	32
OptiMedica Raises US\$35 Million In Venture Financing	33
Nanostim Raises US\$10 Million In Venture Financing	35
Topera Raises US\$4 Million In Venture Financing	36
Tendyne Raises US\$9 Million In Venture Financing	37
Nanostim Raises US\$10 Million In Venture Financing	38
Topera Raises US\$2.8 Million In Venture Financing	39
IDev Technologies Raises US\$0.83 Million In Venture Financing	40
Pharos Capital Group Acquires Majority Stake in TechLab	41

Exponent Private Equity Acquires BBI Diagnostics from Alere for USD162 Million 42

Abbott Lab Enters into Licensing Agreement with SurModics 43

Abbott Labs Enters into Licensing Agreement with Beijing Strong Biotechnologies 44

Axis-Shield Enters into Licensing Agreement with Hangzhou Joinstar Biomedical 45

Insulet Extends Licensing Agreement with Abbott Diabetes Care 46

BioPorto Diagnostics Enters Into Licensing Agreement With Abbott Labs 47

Axis-Shield Diagnostic Enters into Licensing Agreement with Siemens Healthcare Diagnostics 48

Robert Bosch Healthcare Systems Enters Into Licensing Agreement With Abbott Diabetes Care 49

Abbott Enters Into Licensing Agreement With Stanford University For Prostate Cancer Biomarkers 50

Insulet Amends Licensing Agreement With Abbott Diabetes 51

Roxwood Medical Enters into Distribution Agreement with Abbott Vascular 52

Abbott Labs and Bigfoot Biomedical Enter into Agreement 53

Akers Biosciences Enters into Distribution Agreement with First Check Diagnostics 54

Celgene and Agios Pharma Enter into Agreement with Abbott Labs 55

Diasend Partners with Abbott Labs 56

MATTER Enters into Agreement with Abbott 57

Abbott Enters into Agreement with GE Healthcare 58

Abbott Labs Enters into Agreement with Sekisui Diagnostics for Coagulation Testing 59

Advanced Biological Enters into Agreement with Abbott for HIV Genotyping Data Analysis Software 60

Abbott Labs Enters into Co-Development Agreement with US Department of Defense 61

Abbott Molecular Enters into Co-Development Agreement with Biocartis 62

Idera Pharma Enters Into Co-Development Agreement With Abbott Molecular For In Vitro Companion Diagnostic Test 63

Abbott Enters Into Distribution Agreement With R-Pharm For Diabetes Care Products 64

St. Jude Medical Enters Into Distribution Agreement With Spinal Modulation For Axium Neurostimulator System 65

Epizyme Enters Into Co-Development Agreement With Abbott Labs 66

BioGenex Labs Enters Into Co-Marketing Agreement With Abbott Molecular 67

Cellavision Enters Into Distribution Agreement With Abbott 68

Abbott Molecular Enters Into Agreement With Janssen Biotech And Pharmacyclics For Leukemia Test 69

BioView Enters Into Agreement With Abbott To Develop Automated Cancer Screening System 70

Abaxis Enters Into Distribution Agreement With Abbott Point of Care For Piccolo Blood Chemistry System 71

Alere Enters Into Co-Development Agreement With AT&T	72
Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo	73
Abbott Vascular Enters Into Co-Marketing Agreement With St. Jude Medical	74
Abbott Enters Into Co-Development Agreement With Genetics Lab For Molecular Assay Development	75
Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCT Assay For Sepsis	76
Novartis Enters into Licensing Agreement with Abbott Vascular for Everolimus	77
Abbott Labs Plans to Raise USD3 Billion in Public Offering of Shares	78
Abbott Labs Raises USD1.33 Billion in Public Offering of 1.5% Bonds Due 2026	79
Abbott Labs Raises USD1.33 Billion in Public Offering of 0.875% Bonds Due 2023	80
Abbott Labs Raises USD1.33 Billion in Public Offering of Bonds Due 2020	81
Abbott Labs Raises USD3 Billion in Public Offering of 3.75% Notes due 2026	82
Abbott Labs Raises USD1.5 Billion in Public Offering of 3.4% Notes Due 2023	84
Abbott Labs Raises USD1.65 Billion in Public Offering of 4.75% Notes due 2036	86
Abbott Labs Raises USD2.85 Billion in Public Offering of 2.9% Notes due 2021	88
Abbott Labs Raises USD2.85 Billion in Public Offering of 2.35% Notes due 2019	90
Abbott Labs Raises USD3.25 Billion in Public Offering of 4.9% Notes due 2046	92
Alere Raises USD425 Million in Private Placement of 6.37% Notes Due 2023	94
Abbott Labs Raises USD750 Million in Public Offering of 2.55% Notes Due 2022	95
Abbott Labs Raises USD1 Billion in Public Offering of 2.55% Notes Due 2025	96
Abbott Labs Raises USD2.5 Billion in Public Offering of 2% Notes Due 2020	97
Alere Completes Private Placement Of Notes Due 2020 For US\$425 Million	98
St. Jude Medical Completes Public Offering Of Notes Due 2043 For US\$700 Million	99
St. Jude Medical Completes Public Offering Of Notes Due 2023 For US\$900 Million	101
Alere Completes Private Placement Of Notes Due 2018 For US\$450 Million	103
Abbott Completes Private Placement Of Notes Due 2018 For US\$1 Billion	104
Abbott Completes Private Placement Of Notes Due 2022 For US\$3.1 Billion	105
Abbott Completes Private Placement Of Notes Due 2042 For US\$2.6 Billion	106
Abbott Completes Private Placement Of Notes Due 2015 For US\$3.5 Billion	107
Abbott Completes Private Placement Of Notes Due 2017 For US\$4 Billion	108
Abbott Completes Private Placement Of Notes Due 2015 For US\$500 Million	109
Quidel Acquires Triage and BNP Business from Alere	110

Terumo Acquires Portion of Vascular Closure Portfolio and Other Assets from St. Jude Medical and Abbott Labs for USD1.12 Billion 112

QIAGEN Acquires Circulating Tumor Cell Technology from AdnaGen 114

Coppersmith Capital Management Reportedly Wants Alere To Explore Sale Of Its Drug Testing And Toxicology Businesses For Up To US\$5 Billion 115

Vascular Solutions Acquires Venture Catheter From St. Jude Medical For US\$3 Million 116

Siemens Healthineers Acquires Epocal from Alere 117

Abbott Labs Acquires Alere 118

Johnson & Johnson Acquires Abbott Medical Optics from Abbott Laboratories for USD4.32 Billion 120

Abbott Labs Acquires St. Jude Medical for up to USD23.6 Billion 121

Abbott Labs Acquires Kalila Medical 123

St. Jude Medical Acquires Thoratec for USD3.3 Billion 124

Abbott Labs Acquires Remaining Stake in Tendyne for USD250 Million 126

Abbott Labs Enters into Option Agreement to Acquire Cephea Valve Technologies 127

Abbott Labs Acquires Omnilab 128

Alere Acquires US Diagnostics USD60 Million 129

St. Jude Medical Acquires Spinal Modulation 130

Abbott Labs Acquires Topera 131

Abbott Labs Receives Right to Acquire Advanced Cardiac Therapeutics 132

Ron Zwanziger Plans to Acquire Alere for USD3.82 Billion 133

Jude Medical Completes Acquisition of NeuroTherm for USD200 Million 134

St. Jude Medical Completes Acquisition of Remaining 81% Stake in CardioMEMS for USD450 Million 135

St. Jude Medical Completes Acquisition Of Nanostim For US\$123.5 Million 137

Abbott Laboratories Completes Acquisition Of IDev Technologies 139

Abbott Labs Completes Acquisition Of OptiMedica For Up To USD410 Million 141

St. Jude Medical Acquires Endosense, Developer Of Cardiovascular Devices 143

Alere Completes Acquisition Of Epocal For Up To US\$241 Million 145

Abbott, Johnson & Johnson And Sanofi Mull Individual Acquisition Of Bausch & Lomb 147

Alere Acquires eScreen for USD296 Million 149

Arriva Medical Acquires AmMed Direct For US\$23 Million 151

STARLIMS Technologies Acquires Distribution Partners 152

Arriva Medical Acquires Direct Diabetic Source 153

Abbott Laboratories, Key Competitors 154

Abbott Laboratories, Key Employees 155

Abbott Laboratories, Other Locations 157

Abbott Laboratories, Subsidiaries 157

# List Of Figures, Charts and Diagrams in Abbott Laboratories (ABT) - Medical Equipment - Deals and Alliances Profile [Report Updated: 16-10-2018]

## List of Figures

Abbott Laboratories, Medical Equipment, Deals by Type, 2012 to YTD 2018 2

Abbott Laboratories, Medical Equipment, Deals By Year, 2012 to YTD 2018 2

Abbott Laboratories, Medical Equipment, Deals By Region, 2012 to YTD 2018 2

Abbott Laboratories, Medical Equipment, Deals By Market, 2012 to YTD 2018 2

Abbott Laboratories, Medical Equipment, Deals By Year, 2012 to YTD 2018 10

Abbott Laboratories, Medical Equipment, Deals by Type, 2012 to YTD 2018 11

Abbott Laboratories, Medical Equipment, Deals By Region, 2012 to YTD 2018 12

Abbott Laboratories, Medical Equipment, Deals by Market, 2012 to YTD 2018 13

# How to Buy...

Abbott Laboratories (ABT) - Medical Equipment - Deals and Alliances Profile [Report Updated: 16-10-2018]

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/225175>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and either **Scan** this page **and email** it to us at [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com) or **Fax** it to us at +44 (0)1305 791844. We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$250** | Single User Price
- \$500** | Site License Price
- \$750** | Global License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)1300 321501

We will be delighted to give you our personal attention.